Contact

Wide Anchor 57 Home About Services Evidence Summary Safety Checklist Research Roadmap Contact Evidence-first orientation Ibogaine For Multiple Sclerosis: A Checklist A calm, practical guide to limited evidence, substantial safety concerns, and the questions that should come before any decision about an unproven intervention. Bottom line Ibogaine is not an established treatment for multiple sclerosis. Current interest is a research hypothesis, not proof of disease modification, remyelination, or symptom relief. 01 — Ground the question Understanding multiple sclerosis (MS) Before weighing an experimental idea, separate the daily burden of symptoms from claims about changing the disease itself. Multiple sclerosis is a chronic autoimmune disease affecting the brain, spinal cord, and optic nerves. The immune system mistakenly attacks the myelin sheath, the protective covering around nerve fibers, creating inflammation and nerve damage across the central nervous system. A concise overview from the National Institute of Neurological Disorders and Stroke describes why the condition can look very different from one person to another. About 2.8 million people worldwide live with multiple sclerosis, and onset most commonly occurs between ages 20 and 40. Fatigue, numbness, weakness, vision problems, balance issues, pain, and cognitive impairment can all occur. MS symptoms may fluctuate during remission periods, especially in relapsing remitting disease, while progressive MS can involve more gradual disability. This neurological disorder is not one uniform experience. That matters when people interpret a better or worse week as a treatment effect. Disease progression, MRI activity, relapse rate, functional change, and symptom management are related but different outcomes. Standard treatment options include disease-modifying therapies, rehabilitation, symptom-directed care, and support for mental health. No discussion of ibogaine treatment should imply that it replaces an MS cli

How to reach us